Sarah Grinshtein


Sarah Grinshtein is an associate in Weil’s Mergers & Acquisitions practice and is based in New York. Sarah participates in the representation of public and private companies in mergers, acquisitions and divestitures.

Sarah has been part of the teams advising:

  • 8 Rivers Capital, LLC in its $100 million sale of a minority stake to SK Group (SK) and the formation of a joint venture with SK focused on the decarbonization of Korean and key Asian markets
  • Covetrus, Inc. in its $4 billion sale to CD&R, a holder of approximately 24% of Covetrus' outstanding common stock, and TPG
  • Sanofi in its up to $1.225 billion acquisition of Amunix Pharmaceuticals, Inc.

Prior to joining Weil, Sarah was an associate at another international law firm.

During law school, Sarah served as a judicial intern to Chief Justice Sherry Radack of the Texas First Court of Appeals and at the Executive Office for Immigration Review.

Sarah received her J.D. from The University of Texas School of Law and her B.A. from Yeshiva University.

Sarah is proficient in Hebrew.

Firm News & Announcements

Firm News & Announcements